Caloric Restriction Alone and with Exercise Improves CVD Risk in Healthy Non-obese Individuals
Overview
Authors
Affiliations
Unlabelled: Calorie restriction (CR) delays the development of age-associated disease and increases lifespan in rodents, but the effects in humans remain uncertain.
Purpose: Determine the effect of 6 months of CR with or without exercise on cardiovascular disease (CVD) risk factors and estimated 10-year CVD risk in healthy non-obese men and women.
Methods: Thirty-six individuals were randomized to one of three groups for 6 months: Control, 100% of energy requirements; CR, 25% calorie restriction; CR+EX, 12.5% CR+12.5% increase in energy expenditure via aerobic exercise. CVD risk factors were assessed at baseline, 3 and 6 months.
Results: After 6 months, CR and CR+EX lost approximately 10% of body weight. CR significantly reduced triacylglycerol (-31+/-15mg/dL) and factor VIIc (-10.7+/-2.3%). Similarly CR+EX reduced triacylglycerol (-22+/-8mg/dL) and additionally reduced LDL-C (-16.0+/-5.1mg/dL) and DBP (-4.0+/-2.1mmHg). In contrast, both triacylglycerol (24+/-14mg/dL) and factor VIIc (7.9+/-2.3%) were increased in the Control group. HDL-cholesterol was increased in all groups while hsCRP was lower in the Controls versus CR+EX. Estimated 10-year CVD risk significantly declined from baseline by 29% in CR (P<0.001) and 38% in the CR+EX (P<0.001) while remaining unchanged in the Control group.
Conclusions: Based on combined favorable changes in lipid and blood pressure, caloric restriction with or without exercise that induces weight loss favorably reduces risk for CVD even in already healthy non-obese individuals.
Omotoso A, Reyer H, Oster M, Ponsuksili S, Metzler-Zebeli B, Wimmers K Metabolites. 2024; 14(11).
PMID: 39590861 PMC: 11596519. DOI: 10.3390/metabo14110625.
The Hidden Dangers of Sedentary Living: Insights into Molecular, Cellular, and Systemic Mechanisms.
Guerreiro Diniz D, Bento-Torres J, da Costa V, Carvalho J, Tomas A, Galdino de Oliveira T Int J Mol Sci. 2024; 25(19).
PMID: 39409085 PMC: 11476792. DOI: 10.3390/ijms251910757.
Poljsak B, Milisav I Int J Mol Sci. 2024; 25(12).
PMID: 38928027 PMC: 11203720. DOI: 10.3390/ijms25126321.
Nrf2 Signaling Pathway as a Key to Treatment for Diabetic Dyslipidemia and Atherosclerosis.
Yi M, Toribio A, Salem Y, Alexander M, Ferrey A, Swentek L Int J Mol Sci. 2024; 25(11).
PMID: 38892018 PMC: 11172493. DOI: 10.3390/ijms25115831.
Sones B, Devlin B Nutr Rev. 2024; 83(2):230-248.
PMID: 38728010 PMC: 11723158. DOI: 10.1093/nutrit/nuae044.